Onureg (azacitidine)

pCPA File Number: 21641

Negotiation Status:

Concluded with an LOI

Indication(s):

Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)

Sponsor/Manufacturer:

Celgene Inc.

CADTH Project Number:

PC0245

pCPA Engagement Letter Issued:

2022-01-27

Negotiation Process Concluded:

2022-06-07